Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Sells $44,884.08 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Sravan Kumar Emany sold 11,001 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares in the company, valued at approximately $1,263,053.76. This represents a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ IRWD opened at $3.44 on Friday. The stock’s 50-day moving average is $4.23 and its 200 day moving average is $5.36. Ironwood Pharmaceuticals, Inc. has a 1-year low of $3.26 and a 1-year high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $91.60 million during the quarter, compared to analysts’ expectations of $91.22 million. During the same period last year, the company posted $0.12 EPS. Ironwood Pharmaceuticals’s revenue for the quarter was down 19.4% on a year-over-year basis. Equities research analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IRWD. CWM LLC boosted its holdings in Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 2,345 shares during the period. KBC Group NV lifted its position in Ironwood Pharmaceuticals by 59.3% in the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,198 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the first quarter valued at approximately $91,000. GAMMA Investing LLC grew its holdings in shares of Ironwood Pharmaceuticals by 344.1% in the second quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 8,156 shares during the last quarter. Finally, EntryPoint Capital LLC increased its stake in shares of Ironwood Pharmaceuticals by 517.4% in the first quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company’s stock worth $92,000 after buying an additional 8,874 shares during the period.

Analyst Ratings Changes

Several equities analysts recently commented on IRWD shares. Capital One Financial cut shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $12.00 to $4.00 in a research note on Thursday, August 8th. Craig Hallum lowered their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Wells Fargo & Company reduced their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. Leerink Partners initiated coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 price target on the stock. Finally, Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.